Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment.
Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Ekhart C, et al. Cancer Treat Rev. 2009 Feb;35(1):18-31. doi: 10.1016/j.ctrv.2008.07.003. Epub 2008 Sep 3. Cancer Treat Rev. 2009. PMID: 18771857 Review.
Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Ekhart C, et al. Clin Cancer Res. 2006 Nov 1;12(21):6502-8. doi: 10.1158/1078-0432.CCR-05-1076. Clin Cancer Res. 2006. PMID: 17085665
Carbamazepine induces bioactivation of cyclophosphamide and thiotepa.
Ekhart C, Rodenhuis S, Beijnen JH, Huitema AD. Ekhart C, et al. Cancer Chemother Pharmacol. 2009 Feb;63(3):543-7. doi: 10.1007/s00280-008-0758-y. Epub 2008 Apr 24. Cancer Chemother Pharmacol. 2009. PMID: 18437385
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Ekhart C, et al. Pharmacogenet Genomics. 2008 Jun;18(6):515-23. doi: 10.1097/FPC.0b013e3282fc9766. Pharmacogenet Genomics. 2008. PMID: 18496131
Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Ekhart C, et al. Pharmacogenet Genomics. 2008 Nov;18(11):1009-15. doi: 10.1097/FPC.0b013e328313aaa4. Pharmacogenet Genomics. 2008. PMID: 18854779 Clinical Trial.
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Ekhart C, et al. Br J Clin Pharmacol. 2009 Jan;67(1):50-60. doi: 10.1111/j.1365-2125.2008.03321.x. Epub 2008 Nov 17. Br J Clin Pharmacol. 2009. PMID: 19076156 Free PMC article.
RESULTS: The polymorphisms CYP2B6 C1459T, CYP3A4*1B, CYP3A5*3, GSTA1 (C-69T, G-52A) and GSTP1 C341T had a significant effect on clearance of thiotepa or tepa. ...
RESULTS: The polymorphisms CYP2B6 C1459T, CYP3A4*1B, CYP3A5*3, GSTA1 (C-69T, G-52A) and GSTP1 C341T had a significant effect on clear …
Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
Ekhart C, Rodenhuis S, Beijnen JH, Huitema AD. Ekhart C, et al. Ther Drug Monit. 2009 Feb;31(1):95-103. doi: 10.1097/FTD.0b013e318194e484. Ther Drug Monit. 2009. PMID: 19155964
Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS).
Ekhart C, Gebretensae A, Rosing H, Rodenhuis S, Beijnen JH, Huitema AD. Ekhart C, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jul 1;854(1-2):345-9. doi: 10.1016/j.jchromb.2007.04.024. Epub 2007 Apr 25. J Chromatogr B Analyt Technol Biomed Life Sci. 2007. PMID: 17485255
22 results
Jump to page
Feedback